StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ASBP yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $5.63 | $5.61 | -0.36% | 0.1M |
| 05-18 | $5.66 | $6.68 | +18.02% | 5.2M |
| 05-19 | $6.17 | $5.83 | -5.51% | 0.2M |
| 05-20 | $5.94 | $6.03 | +1.52% | 0.1M |
| 05-21 | $5.91 | $5.59 | -5.41% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 |
|---|---|---|
Revenue | $28.35K | $6.20K |
Operating Income | $-1.65M | $-19.35M |
Net Income | $-3.22M | $-24.48M |
EPS (Diluted) | $-20.57 | $-16.38 |
Total Assets | $7.12M | $1.31M |
Total Liabilities | $3.25M | $7.69M |
Cash & Equivalents | $5.86M | $1.00M |
Free Cash Flow OCF − CapEx | Not available | Not available |
Shares Outstanding | 167.47K | 117.78K |
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.